ZYNYZ

PeakmAb

retifanlimab-dlwr

BLAINTRAVENOUSINJECTABLEPriority Review

Approved

Mar 2023

Lifecycle

Peak

Competitive Pressure

30/100

Mechanism of Action

Programmed Death Receptor-1-directed Antibody Interactions

Pharmacologic Class:

Programmed Death Receptor-1 Blocking Antibody

Company

DE - Wilmington

External Resources

Full prescribing information

FDA approval history

Drug nomenclature & identifiers